AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
BioMarin Q2 2026 total revenue rose 20% YoY to $989.7M, led by VOXZOGO and the Amicus-acquired GALAFOLD and POMBILITI + OPFOLDA, while net income fell to $44.8M on acquisition-related interest, amortization and SG&A.
Biggest Revenue Drivers
VOXZOGO$252.5M+14% YoY
Higher sales volume from new patients initiating therapy across all regions.
GALAFOLD$105.7MAcquired April 27, 2026
Revenue recognized from acquisition date following Amicus acquisition.
Biggest Revenue Drivers
Total revenue: $989.7M+20% YoY
VOXZOGO$252.5M+14% YoY
Higher sales volume from new patients initiating therapy across all regions.
GALAFOLD$105.7MAcquired April 27, 2026
Revenue recognized from acquisition date following Amicus acquisition.
POMBILITI + OPFOLDA$30.3MAcquired April 27, 2026
Revenue recognized from acquisition date following Amicus acquisition.
PALYNZIQ$135.2M+28% YoY
Higher sales volume from new patients initiating therapy, primarily in the U.S.
Largest Expense Items
Selling, general and administrative$395.5M+70% YoY
Driven by integration and restructuring charges for Amicus and incremental administrative costs for corporate initiatives; S&M rose on acquired products and VOXZOGO expansion.
Cost of sales$202.8M+35% YoY
Increased sales volume and amortization of acquired inventory fair value step-up from Amicus products.
Research and development$207.0M+28% YoY
Higher spend on BMN 401 and R&D for two marketed products acquired from Amicus, partly offset by discontinued early-pipeline programs.
Intangible asset amortization$73.5M+$68.7M YoY
Amortization of intangible assets acquired from Amicus on April 27, 2026.
Margins: Gross margin declined to 79.5% from 81.8% in the prior-year quarter, attributed to higher sales volume and amortization of acquired inventory fair value step-up associated with Amicus products. Interest expense also rose sharply following acquisition financing.
Watch Items from the Filing
Total debt rose to approximately $4.3B (undiscounted) from about $1.5B at March 31, 2026, after financing the ~$5.3B Amicus acquisition; interest expense was $63.3M in the quarter.
Three customers accounted for 13%, 11% and 11% of Q2 2026 net product revenues, totaling 35%.
BMN 401 did not meet one of two co-primary endpoints in May 2026; development was discontinued across all indications in August 2026.
Restructuring charges of $56.4M in the quarter related to Corporate initiatives and Amicus integration, with further reductions expected through April 2027.
Amicus contributed $136.0M of revenue but a net loss of $91.9M since acquisition; sNDA for VOXZOGO in achondroplasia has a PDUFA date of February 28, 2027.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About BIOMARIN PHARMACEUTICAL INC (BMRN): stock profile, AI score and financials
BIOMARIN PHARMACEUTICAL INC (BMRN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMRN at 58.0/100 on a composite quality score built from its SEC filings, placing it at rank #1,046 of 2,925 stocks — the top half of the AI-ranked universe. BMRN scores in the top quartile across earnings quality (97.6), free cash flow (75.5). Areas of concern include profitability (28.8) and institutional flow (37.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIOMARIN PHARMACEUTICAL INC reports quarterly revenue of $989.7M, net income of $44.8M, an operating margin of 11.2%. Top institutional holders of BMRN by reported 13-F value include BlackRock, DODGE & COX, PRIMECAP MANAGEMENT, based on the most recent SEC filings. BMRN trades on the Nasdaq exchange and files with the SEC under CIK 1048477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOMARIN PHARMACEUTICAL INC directly from SEC EDGAR.